Little House Capital LLC Makes New $2.08 Million Investment in Pfizer Inc. (NYSE:PFE)

Little House Capital LLC bought a new position in Pfizer Inc. (NYSE:PFE) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 57,947 shares of the biopharmaceutical company’s stock, valued at approximately $2,082,000. Pfizer makes up approximately 1.6% of Little House Capital LLC’s investment portfolio, making the stock its 17th biggest position.

Other hedge funds have also modified their holdings of the company. Heritage Way Advisors LLC increased its holdings in shares of Pfizer by 0.6% during the second quarter. Heritage Way Advisors LLC now owns 57,524 shares of the biopharmaceutical company’s stock valued at $2,492,000 after acquiring an additional 354 shares in the last quarter. Natixis purchased a new position in shares of Pfizer during the second quarter valued at approximately $258,466,000. Machina Capital S.A.S. boosted its position in shares of Pfizer by 14.4% during the second quarter. Machina Capital S.A.S. now owns 43,837 shares of the biopharmaceutical company’s stock valued at $1,899,000 after buying an additional 5,522 shares during the last quarter. Integrated Wealth Concepts LLC boosted its position in shares of Pfizer by 14.2% during the second quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock valued at $2,840,000 after buying an additional 8,445 shares during the last quarter. Finally, Annex Advisory Services LLC boosted its position in shares of Pfizer by 0.7% during the second quarter. Annex Advisory Services LLC now owns 51,785 shares of the biopharmaceutical company’s stock valued at $2,243,000 after buying an additional 382 shares during the last quarter. Institutional investors and hedge funds own 71.52% of the company’s stock.

Several brokerages recently issued reports on PFE. UBS Group reaffirmed a “neutral” rating and set a $43.00 target price on shares of Pfizer in a research report on Monday, August 5th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. DZ Bank raised Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price on the stock in a research report on Wednesday, August 28th. Finally, Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price on the stock in a research report on Tuesday, October 1st. Nine analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $44.02.

PFE stock traded down $0.12 during midday trading on Monday, hitting $36.93. The company’s stock had a trading volume of 11,854,162 shares, compared to its average volume of 23,366,957. The stock’s 50-day moving average price is $36.62 and its 200 day moving average price is $39.26. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 1 year low of $33.97 and a 1 year high of $46.47. The stock has a market cap of $207.30 billion, a price-to-earnings ratio of 12.31, a PEG ratio of 2.11 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.13. Pfizer had a return on equity of 28.61% and a net margin of 30.57%. The business had revenue of $12.68 billion for the quarter, compared to analysts’ expectations of $12.37 billion. During the same quarter in the previous year, the firm earned $0.78 earnings per share. The business’s revenue was down 4.6% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.36 dividend. The ex-dividend date is Thursday, November 7th. This represents a $1.44 annualized dividend and a yield of 3.90%. Pfizer’s dividend payout ratio is currently 48.00%.

In other news, Director Scott Gottlieb bought 3,000 shares of the stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the purchase, the director now directly owns 3,000 shares in the company, valued at approximately $104,160. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Pfizer Inc bought 50,000 shares of the stock in a transaction on Tuesday, September 17th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: Why are percentage gainers important?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.